Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Greenlight’s Einhorn Fined by British FSA for Insider Trading

GREENLIGHT CAPITALDavid Einhorn, founder and manager of Greenlight Capital, was fined today by British regulators. “The Financial Services Authority ordered Einhorn to pay £7.2 million (US$11.2 million), including a £3.7 million fine, reports FINAlternatives. “The agency said that Einhorn ordered Greenlight to sell its entire stake in Punch Taverns after learning that the company was about to announce a round of equity financing.” At the time Einhorn made his call, “Greenlight owned 13.3% of Punch’s stock.”

“The FSA said that Einhorn learned on June 9, 2009, from a broker working for Punch that the company was near an equity fundraising. Einhorn then instructed his hedge fund to sell its stake.” Greenlight sold 11.7 million shares, cutting its stake in Punch to 8.9% and, in doing so, avoided “£5.8 million in losses after Punch announced its fundraising on June 15.” Einhorn said he did not believe he was violating market abuse rules. He said that he still believes he did nothing wrong and agreed to the fine “rather than continue an arduous fight.” The FSA accepted this while saying that  the Punch tip “was inside information and Einhorn should have appreciated this.”

Einhorn said that Greenlight’s investors would not bear the burden of the fine.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!